COVID vaccines: the heart of the crisis

Myocarditis is a major problem; here are details on latest research

People need a clear understanding of myocarditis:

Myocarditis is a condition in which the heart muscle, also called the myocardium, becomes inflamed. This inflammation can cause the heart muscle to become weakened, stiff, or enlarged, which can lead to problems with the heart's ability to pump blood effectively. It has become increasingly clear that this vaccine impact can cause short and long term problems, including heart attack, cardiac problems and death.

Summaries and links for important medical articles:

• FDA finally admits in its own report on 65+ mRNS recipients: Risk of lung clots up 50% - Risk of heart attacks up 40%+ https://www.sciencedirect.com/science/article/pii/S0264410X22014931 : Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.

• Jan 2022, JAMA study found myocarditis risk increased in multiple age, sex groups after mRNA COVID-19 vaccination, highest in young men. https://jamanetwork.com/journals/jama/fullarticle/2788346 :Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. “In this descriptive study of 1626 cases of myocarditis in a national passive reporting system, the crude reporting rates within 7 days after vaccination exceeded the expected rates across multiple age and sex strata. The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively).”

• Study of VAERS data between Jan-Jun 2021 found highest rate of myocarditis in young boys 12-15 after dose 2 of mRNA COVID-19 vaccination. https://onlinelibrary.wiley.com/doi/10.1111/eci.13759 :BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis. “Cases of myo/pericarditis (n = 253) included 129 after dose 1 and 124 after dose 2; 86.9% were hospitalized. Incidence per million after dose two in male patients aged 12–15 and 16–17 was 162.2 and 93.0, respectively. Weighing post-vaccination myo/pericarditis against COVID-19 hospitalization during delta, our risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity. In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates. In the setting of omicron, one dose may be protective in nonimmune children, but dose two does not appear to confer additional benefit at a population level.”

• This slide presentation to the CDC and FDA on myocarditis should have rung some IMMEDIATE alarms bells - but we went on vaxxing the young lads anyway. https://fda.gov/media/159007/download :Update on myocarditis following mRNA
  COVID-19 vaccination.

• Study in Nature found increased risks of myocarditis and pericarditis in France after Covid-19 mRNA vaccines, particularly after 2nd dose and in age 18-24 yrs, both male and female were affected. https://www.nature.com/articles/s41467-022-31401-5 :Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. “Cases of myocarditis and pericarditis have been reported following the receipt of Covid-19 mRNA vaccines. As vaccination campaigns are still to be extended, we aimed to provide a comprehensive assessment of the association, by vaccine and across sex and age groups. Using nationwide hospital discharge and vaccine data, we analysed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 and 30 (95% CI, 21 to 43) for the mRNA-1273 vaccine. The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.”

• CDC report 2022 found 14 cases of myocarditis or pericarditis among 102,091 males aged 16-17 who received Pfizer-BioNTech Covid-19 vaccine, significant departure from reported rates in 2021, showing concerns labeled as misinformation are real. https://thefederalist.com/2022/09/09/cdc-admits-post-vaccine-myocarditis-concerns-that-were-labeled-covid-misinformation-are-legit/

  CDC Admits Post-Vaccine Myocarditis Concerns That Were Labeled Covid Misinformation Are Legit.

• Study found myocarditis/pericarditis as rare side effect of mRNA COVID-19 vaccines, disproportionately affects young male adolescents, commonly after 2nd dose of primary series and 1st booster. https://www.acpjournals.org/doi/10.7326/M22-2274 CDC Admits Post-Vaccine Myocarditis Concerns That Were Labeled Covid Misinformation Are Legit. Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States.

  “In this population-based surveillance, we found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200 000 doses after the first dose and 1 in 30 000 doses after second dose of the primary series, and 1 in 50 000 doses after the first booster. The incidence varied markedly by age and sex, however, with a disproportionate number of cases occurring in male persons, notably among adolescents after dose 2 and first boosters.”

• The estimated MMRRs and SMR were about 4 times higher than the MMRRs and SMR. The study concludes that the SARS-CoV-2 vaccine is associated with a higher risk of myocarditis death in all age groups, including the elderly. The risk may be 4 times or higher than the apparent risk of myocarditis death. https://www.medrxiv.org/content/10.1101/2022.10.13.22281036v1.full.pdf SARS-CoV-2 vaccine and increased myocarditis mortality risk:2
  A population based comparative study in Japan. “Myocarditis mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) after10
  receiving SARS-CoV-2 vaccine compared with that in the reference population (previous 3 years) were significantly higher not only in young adults (highest in the 30s with MMRR of 6.69) but also in the elderly. Standardised mortality ratio (SMR) for myocarditis was 1.65 (1.07 to 2.55) for those 60 years or older and 2.01 (1.44 to 2.80) in overall age. The risk of myocarditis mortality in the SARS-CoV-2 vaccinated population may be 4 times or higher than the apparent MMRRs15
  considering healthy vaccinee effect. Unreported post-vaccination deaths should also be considered as suggested by the extremely high myocarditis mortality odds ratio (205.60; 133.52 to 311.94).”

• Markedly elevated levels of full-length spike protein were detected in the plasma of individuals with post-vaccine myocarditis, whereas no free spike was detected in asymptomatic vaccinated control subjects. It suggests that the cause of myocarditis may be linked with spike antigen. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061025 Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis. “free spike antigen was detected in the blood of adolescents and young adults who developed post-mRNA vaccine myocarditis, advancing insight into its potential underlying cause.”

• The risk ratio for the mRNA vaccines combined is 1.43 which means that recipients are 43% more likely to have a serious adverse event. https://www.sciencedirect.com/science/article/pii/S0264410X22010283 Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. “Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI −0.4 to 20.6 and −3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI –23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI −3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39).”

• You’re going to have to vax 35K young adults to prevent one hospitalization and in doing so you’re going to send nearly 20 of these folks into a serious adverse reaction from the vax. https://jme.bmj.com/content/early/2022/12/05/jme-2022-108449 COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. “In 2022, students at North American universities with third-dose COVID-19 vaccine mandates risk disenrolment if unvaccinated. To assess the appropriateness of booster mandates in this age group, we combine empirical risk-benefit assessment and ethical analysis. To prevent one COVID-19 hospitalisation over a 6-month period, we estimate that 31 207–42 836 young adults aged 18–29 years must receive a third mRNA vaccine. Booster mandates in young adults are expected to cause a net harm: per COVID-19 hospitalisation prevented, we anticipate at least 18.5 serious adverse events from mRNA vaccines, including 1.5–4.6 booster-associated myopericarditis cases in males (typically requiring hospitalisation). We also anticipate 1430–4626 cases of grade ≥3 reactogenicity interfering with daily activities (although typically not requiring hospitalisation). University booster mandates are unethical because they: (1) are not based on an updated (Omicron era) stratified risk-benefit assessment for this age group; (2) may result in a net harm to healthy young adults; (3) are not proportionate: expected harms are not outweighed by public health benefits given modest and transient effectiveness of vaccines against transmission; (4) violate the reciprocity principle because serious vaccine-related harms are not reliably compensated due to gaps in vaccine injury schemes; and (5) may result in wider social harms. We consider counterarguments including efforts to increase safety on campus but find these are fraught with limitations and little scientific support.”